1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

600671.SS
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,LtdCN flagShanghai Stock Exchange
17.08
CNY
-0.34
- -
2.08BMarket Cap
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
600671.SS
(Shanghai Stock Exchange)

Recent

price

17.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.86
2.31
1.88
2.67
1.1
0.79
1.02
1.52
2.9
2.44
1.68
1.18
0.89
1
1.78
1.74
2.14
Revenue per Share
-0.07
0.22
-0.73
0.02
0.02
-0.18
0.01
0.07
-0.08
0.42
-0.33
-0.24
-0.55
-0.31
0.13
0.14
0.36
Basic EPS, GAAP
-0.21
-0.11
-0.17
0.01
-0.22
-0.12
-0.19
-0.32
0.27
0.55
-0.16
-0.25
-0.19
-0.24
-0.47
-0.16
-0.3
Free Cash Flow per Basic Share
0.05
0.06
0.08
0.08
0.05
0.06
0.06
0.08
0.07
0.05
0.06
0.05
0.04
0.05
0.07
0.05
0.07
Dividend per Share
0.5
0.75
-0.01
0.01
0.03
-0.15
-0.14
-0.07
-0.17
0.21
-0.12
-0.35
-0.92
-1.23
-1.11
-0.96
-1.02
Book Value per Share
1.13
1.43
0.68
0.81
0.58
0.45
0.47
0.58
0.14
0.53
0.67
0.45
-0.02
0.4
0.64
0.72
0.71
Tangible Book Value per Share
126
120
122
105
136
120
122
116
123
122
123
124
122
122
122
122
122
Basic Weighted Avg Shares
234
277
229
281
149
95
124
176
358
297
207
147
109
122
217
212
261
Sales/Revenue/Turnover
1.61
5.5
-14.76
3.01
5.53
-15.46
-3.29
-0.08
2.58
-2.96
-2.42
-12.43
-26.11
-17.97
15.74
8.11
23.49
Operating Margin (%)
8
7
8
7
6
9
9
9
13
13
9
12
18
15
19
25
- -
Depreciation Expense
-9
26
-89
2
3
-22
1
8
-10
51
-41
-30
-68
-38
15
18
44
Net Income, GAAP
- -
10.14
- -
13.14
33.41
- -
37.27
22.27
- -
2.63
- -
- -
- -
- -
24.79
29.55
18.1
Effective Tax Rate (%)
-3.77
9.54
-38.78
0.75
1.82
-22.73
0.98
4.62
-2.76
17.06
-19.61
-20.26
-62
-31.43
7.02
8.32
16.83
Profit Margin (%)
12
45
-40
-12
-36
-82
-86
-23
-101
62
-32
-65
-97
-39
-64
-54
-53
Working Capital
- -
- -
- -
- -
- -
- -
- -
46
6
37
5
5
7
7
10
9
10
LT Debt
154
183
93
95
85
63
66
97
89
133
93
65
5
56
85
94
93
Total Equity
- -
5.19
- -
4.38
3.62
- -
-1.87
-0.06
- -
-4.13
- -
- -
- -
- -
12.92
4.9
27.95
Return on Invested Capital (%)
- -
16.88
- -
7.13
6.68
- -
4.34
9.73
- -
41.35
- -
- -
- -
- -
78.61
54.23
-1,279.52
Return on Capital (%)
-13.05
34.39
- -
- -
120.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
140
135
140
LT Borrowings
- -
- -
- -
LT Finance Leases
10
13
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
122
Market Capitalization
1,070
1,403
1,640

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
223
217
194
Cash, Cash Equivalents & STI
66
37
25
Accounts Receivable, Net
97
112
113
Inventories
52
57
46
Total Current Liabilities
286
271
247
Payables & Accruals
- -
- -
- -
ST Debt
140
135
140
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
112.97%
213.18%
10.55%
Free Cash Flow
-0.98%
16.88%
-66.13%
Net Income, GAAP
-61.86%
-13.49%
15.59%
Sales/Revenue/Turnover
16.17%
6.59%
-2.55%
Total Cash Common Dividend
2.69%
2.19%
-24.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28
32
65
93
217
2025
52
51
53
- -
212
2026
44
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.08
- -
- -
- -
0.13
2025
0.04
- -
- -
- -
0.14
2026
0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.07
2025
0.01
- -
- -
- -
0.05
2026
0.01
- -
- -
- -
- -
Similar Companies
Genovate Biotechnology Co., Ltd. (4130.TWO)
Shangya Technology Co., Ltd. (6130.TWO)
Eli Lilly and Company (LLY)
Nissui Pharmaceutical Co., Ltd. (4550.T)
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
Bayer AG (BAYRY)
Business
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS) is a China-based pharmaceutical company engaged in the research, development, manufacture, and sale of proprietary Chinese medicines and chemical drugs. The company offers core products including Tianmushan brand tablets and capsules for cardiovascular, respiratory, and digestive system treatments; pediatric syrups and granules such as pediatric cough syrup and digestive aids; and external preparations like ointments for skin conditions, alongside active pharmaceutical ingredients (APIs) and herbal extracts used in traditional Chinese medicine formulations. It operates primarily through its manufacturing facilities in Hangzhou and distributes products across mainland China, with additional export activities to select Asian markets. Founded in 1993 and headquartered in Hangzhou, Zhejiang Province, the company focuses on the domestic healthcare sector, serving hospitals, pharmacies, and wholesalers as key customer segments. In recent developments within the last two years, Hangzhou TianMuShan has expanded its production capacity through a strategic investment in a new GMP-certified facility for sterile injectables; formed a partnership with a leading biotech firm for co-development of innovative respiratory therapies; and completed a funding round in 2024 to support R&D in oncology drugs, marking a shift toward high-value biologics alongside its traditional herbal portfolio.